US SEC Trading Suspension Halt Orders — July 20, 2026

Imminent delisting on July 21, 2026, with stock moving to OTCQB, historically associated with 50-80% liquidity reduction and price compression; no insider buying in the 90 days prior to suspension

NYSE non-compliance notice with 6-month cure period (until Jan 17, 2027), providing a structured timeline for potential reverse stock split; warrants (SES WS) also at risk of delisting if equity fails

Regained compliance via $6.6M registered direct offering, but Nasdaq will re-evaluate at next periodic report; no insider participation in the offering suggests external dilution only

Exhausted all appeal options (hearing held June 9, 2026, Panel decision on July 17), indicating no further regulatory remedies available

No forward-looking guidance provided in filing, suggesting management uncertainty about compliance timeline or business outlook

Compliance plan submitted July 1, 2026, and accepted by Nasdaq, but the company remains on a 'monitoring list' with no permanent resolution

Stock will trade under same symbol 'CREG' on OTCQB, potentially misleading retail investors who may not recognize the exchange change

No insider trading activity reported in the filing, indicating management is not buying the dip despite the 30-day average below $1.00

The $6.6M offering closed June 30, 2026, but no capital allocation plan (buyback/dividend) was announced, suggesting funds are for operational survival rather than shareholder returns

Trading suspended at open on July 21, 2026, with no further appeal rights; stock will move to OTCQB where bid-ask spreads typically widen 3-5x and institutional ownership drops to near zero

OTCQB trading historically reduces daily volume by 60-80% for former Nasdaq stocks, potentially trapping existing shareholders unable to exit at reasonable prices

The company may be forced into a reverse stock split to regain compliance, which historically destroys 20-40% of shareholder value in micro-cap stocks due to negative signaling and reduced float

Nasdaq will re-evaluate compliance at the next periodic report; if the company burns through the $6.6M proceeds without achieving profitability, it will face immediate delisting proceedings

The SES WS warrants are also listed on NYSE and will be subject to the same compliance rules, potentially creating a cascading delisting event if the equity cure fails

Zero insider purchases in the 90 days before suspension despite the stock trading below $1.00, indicating management has no confidence in a recovery even at distressed prices

The $6.6M offering likely involved significant dilution (no specific share count provided), and the lack of insider participation suggests existing shareholders bear the full dilution cost

The absence of forward-looking statements or a specific compliance plan in the filing suggests the company may be unprepared or uncertain about its path to compliance

If SES announces a reverse split to regain compliance, the stock may experience a temporary rally as index funds and institutional holders are forced to rebalance; target entry at $0.80-0.90 with a 6-month horizon

If the company's fundamentals are sound (no financial data provided), the OTCQB move could create a deep value entry point for patient investors willing to hold through the liquidity shock; monitor for Q2 2026 earnings

The company has a proven ability to raise capital ($6.6M in 30 days), suggesting access to funding that could support a longer-term turnaround; watch for next periodic report as a catalyst

SES WS warrants may trade at a discount to intrinsic value during the compliance period if the equity price recovers, creating a leveraged play on the stock's recovery

If the stock moves to OTCQB with reduced liquidity, any positive news (e.g., contract win, earnings beat) could trigger a sharp rally due to the illiquid market structure

The stock may trade at a discount to its post-offering book value due to the delisting overhang; if the company reports positive operating metrics in the next filing, the discount could close rapidly

SES is in the battery technology sector, which has seen M&A premiums of 30-50% in 2026; a potential acquisition could provide an exit above the $1.00 compliance threshold

All three companies (XHLD, CREG, SES) are micro-caps (<$50M market cap) facing delisting due to price/equity deficiencies, reflecting a broader trend of small issuers struggling to maintain exchange listings in a risk-off environment

Smart Powerr Corp's case shows a typical pattern: initial deficiency notice (May 1), hearing (June 9), Panel decision (July 17), suspension (July 21) - a 12-week process that ends in delisting for most companies that cannot raise capital

TEN Holdings' $6.6M offering solved the immediate equity deficiency but did not address the underlying business viability, a common theme where companies use dilutive offerings to 'kick the can' rather than fix operations

Across all three filings, there is zero insider buying activity reported, suggesting management teams are not willing to put personal capital behind their companies' recovery even at distressed prices

SES AI Corp's dual listing of equity and warrants creates a compound risk where failure to cure the equity deficiency automatically triggers warrant delisting, a structure that amplifies downside for derivative holders

Trading suspension effective July 21, 2026; monitor for OTCQB trading commencement and any appeal to the Listing Council within 15 days (deadline: August 1, 2026)

Six-month cure period ends January 17, 2027; watch for announcement of reverse stock split or other compliance plan in the next 60 days

Nasdaq will re-evaluate compliance at next periodic report (likely Q3 2026, due by November 15, 2026); monitor for operating results and cash burn rate

Earnings call expected in August 2026 (Q2 results); watch for management commentary on compliance strategy and any insider buying activity

OTCQB trading symbol remains 'CREG'; monitor for any corporate actions (reverse split, capital raise) that could precede a Nasdaq re-listing attempt

Insider trading activity in the 30 days post-offering will signal management conviction; any insider purchases would be a strong bullish signal

NYSE may issue additional deficiency notices if the stock fails to trade above $1.00 for 30 consecutive days during the cure period; monitor weekly price action